Zhong Guo Jing Ji Wang·2025-09-05 06:45Core Viewpoint - Baike Bio (688276.SH) reported a significant decline in revenue and net profit for the first half of 2025, indicating potential challenges in its business operations and financial health [1][2]. Financial Performance - The company achieved a revenue of 285 million yuan in the first half of 2025, a decrease of 53.93% compared to the same period last year [2]. - The net profit attributable to shareholders was -73.57 million yuan, down from 138 million yuan in the previous year, reflecting a decline of 153.47% [2]. - The net profit after deducting non-recurring gains and losses was -82.23 million yuan, compared to 135 million yuan in the same period last year, marking a decrease of 160.78% [2]. - The net cash flow from operating activities was 9.32 million yuan, a drop of 88.97% from 84.50 million yuan in the previous year [2]. Asset and Equity Position - As of the end of the reporting period, the net assets attributable to shareholders were 4.07 billion yuan, down 3.47% from 4.22 billion yuan at the end of the previous year [2]. - The total assets amounted to 5.26 billion yuan, showing a slight increase of 1.15% from 5.20 billion yuan at the end of the previous year [2]. Fundraising and Use of Proceeds - Baike Bio raised a total of 1.50 billion yuan, with a net amount of 1.40 billion yuan after deducting issuance costs, which was 285 million yuan less than originally planned [3]. - The company intended to use the raised funds for various vaccine production projects and research and development, including 182 million yuan for a varicella vaccine project and 865 million yuan for R&D of in-progress products [3]. Stock Performance - The stock price of Baike Bio is currently below its initial offering price, indicating a state of underperformance in the market [1].